PREMIER BIOMEDICAL, INC. (OTCMKTS:BIEI) Files An 8-K Termination of a Material Definitive Agreement

PREMIER BIOMEDICAL, INC. (OTCMKTS:BIEI) Files An 8-K Termination of a Material Definitive Agreement
Item 1.02 – Termination of Material Definitive Agreement

Story continues below

On September 13, 2016, we entered into an operating agreement to form a pain management joint venture company with Advanced Technologies Solutions (ATS), owned by Ronald T. La Borde, a member of our Board of Directors. Details of this agreement were disclosed in our Current Report on Form 8-K filed on September 23, 2016 under Item 1.01, which is incorporated herein by this reference.

On July 5, 2017, we informed ATS that we have opted to terminate the joint venture company agreement. We believe that it is best suited for both parties to conduct their businesses separately.


About PREMIER BIOMEDICAL, INC. (OTCMKTS:BIEI)

Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically focusing the treatment of Cancer, Multiple Sclerosis (MS), Neuropathic Pain, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig’s Disease), Fibromyalgia, Traumatic Brain Injury (TBI), Alzheimer’s disease (AD), and Blood Sepsis and Viremia. The Company intends to develop its Sequential-Dialysis Technique, to target Cancer, Alzheimer’s disease, ALS, Blood Sepsis, Leukemia and other life-threatening cancers. The Sequential-Dialysis Technique is a methodology for the removal of those molecules, which are harmful and responsible for causing diseases. Its Sequential-Dialysis Technique method removes those excitatory neural transmitters that cause the death of those cells. It also intends to develop Feldetrex, a candidate drug, for the treatment of MS, Fibromyalgia and TBI. Feldetrex utilizes a low dosage of Naltrexone to increase endogenous enkephalins10.

An ad to help with our costs